Therapy of inflammatory bowel disease in pregnant women

1. Клинические рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России по диагностике и лечению язвенного колита [Электронный ресурс] [Klinicheskie recommendacii Rossiiskoi gastroenterologicheskoi associacii i Associacii koloproctologov Rossii po diagnostike i lecheniyu yazvennogo kolita in Russian)]. URL: http://www.gastro.ru/userfiles/R_YAZVKOLIT_2017.pdf (Дата обращения: 01.11.2017). 2. Клинические рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России по диагностике и лечению болезни Крона [Электронный ресурс] [Klinicheskie recommendacii Rossiiskoi gastroenterologicheskoi associacii i Associacii koloproctologov Rossii po diagnostike i lecheniyu bolezni Krona (in Russian)]. URL: http://www.gastro.ru/userfiles/R_Krona_2017.pdf (Дата обращения: 01.11.2017). 3. Stein D.J., Shaker R. Inflammatory Bowel Disease. A Point of Care Clinical Guide // Springer International Publishing Switzerland. 2015. 244 р. 4. Kanis S.L., van der Woude C.J. Endoscopy for Inflammatory Bowel Disease During Pregnancy: Only When There Is a Strong Indication // Gastroenterology. 2017. Vol. 153(1). P. 330–331. 5. Циммерман Я.С., Михалева Е.Н. Возможности фармакотерапии при лечении гастроэнтерологических заболеваний в период беременности // Клиническая медицина. 2015. Т. 93(8). С. 8–18 [Cimmerman Y.S., Mihaleva E.N. Vozmozhnosti farmakoterapii pri lechenii gastroenterologicheskih zabolevanii v period beremennosti // Klinicheskaya medicina. 2015. Т. 93(8). S. 8–18 (in Russian)]. 6. Gaidos J.K.J., Kane S.V. Managing IBD Therapies in Pregnancy // Curr Treat Options Gastroenterol. 2017. Vol. 15 (1). Р. 71–83. 7. Van der Woude C.J., Ardizzone S., Bengtson M.B. et al. The Second European Evidenced-Based Consensus on Reproduction and Pregnancy in Inflammatory Bowel Disease // J Crohns Colitis. 2015. Vol. 9 (2). Р. 107–124. 8. Gaidos J.K.J., Kane S.V. Sexuality, Fertility, and Pregnancy in Crohn’s Disease // Gastroenterol. Clin. N. Am. 2017. Vol. 46 (3). Р. 531–546. 9. Maliszewska А.М., Warska A., Cendrowski K., Sawicki W. Inflammatory bowel disease and pregnancy // Ginecologia Polska. 2017. Vol. 88(7). Р. 398–403. 10. Hosseini-Carroll P., Mutyala M., Seth A. et al. Pregnancy and inflammatory bowel diseases: Current perspectives, risks and patient management // World J Gastrointest Pharmacol Ther. 2015. Vol. 6(4). Р. 156–171. 11. Корниенко Е.А. Воспалительные заболевания кишечника у детей. М.: Прима Принт, 2014. 208 с. [Kornienko E.A. Vospalitel’nie zabolevaniya kishechnika u detei. M.: Prima Print, 2014. 208 s. (in Russian)]. 12. Mogadam M., Dobbins 3rd W.O., Korelitz B.I., Ahmed S.W. Pregnancy in inflammatory bowel disease: effect of sulfasalazine and corticosteroids on fetal outcome // Gastroenterology. 1981. Vol. 80(1). P. 72–76. 13. Norgard B., Czeizel A.E., Rockenbauer M. et al. Population-based case control study of the safety of sulfasalazine use during pregnancy // Aliment. Pharmacol. Ther. 2001. Vol. 15(4). P. 483–486. 14. Riley S.A., Lecarpentier J., Mani V. et al. Sulphasalazine induced seminal abnormalities in ulcerative colitis: results of mesalazine substitution // Gut. 1987. Vol. 28(8). P. 1008–1012. 15. Toovey S., Hudson E., Hendry W.F., Levi A.J. Sulphasalazine and male infertility: reversibility and possible mechanism // Gut. 1981. Vol. 22(6). P. 445–451. 16. Mahadevan U.C.D. Aminosalicylate (ASA) use during pregnancy is not associated with increased adverse events or congenital malformations (CM) in women with inflammatory bowel disease (IBD) // Gastroenterology. 2006. Vol.130 (Suppl 2). P. A40. 17. Colombel J.F., Brabant G., Gubler M.C. et al. Renal insufficiency in infant: side-effect of prenatal exposure to mesalazine? // Lancet. 1994. Vol. 344(8922). P. 620–621. 18. Rahimi R., Nikfar S., Rezaie A., Abdollahi M. Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: a meta-analysis. Reprod // Toxicol. 2008. Vol. 25(2). P. 271–275. 19. Borch J., Metzdorff S.B., Vinggaard A.M. et al. Mechanisms underlying the antiandrogenic effects of diethylhexyl phthalate in fetal rat testis // Toxicology. 2006. Vol. 223(1–2). P. 144–155. 20. Hernandez-Diaz S., Su Y.C., Mitchell A.A. et al. Medications as a potential source of exposure to phthalates among women of childbearing age // Reprod. Toxicol. 2013. Vol. 37. P. 1–5. 21. Armenti V.T., Daller J.A., Constantinescu S. et al. Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation // Clin. Transpl. 2002. P. 121–130. 22. Habal F.M., Huang V.W. Review article: a decision-making algorithm for the management of pregnancy in the inflammatory bowel disease patient // Aliment. Pharmacol. Ther. 2012. Vol. 35(5). P. 501–515. 23. Khan A.A., Rodriguez A., Kaakinen M. et al. Does in utero exposure to synthetic glucocorticoids influence birthweight, head circumference and birth length? A systematic review of current evidence in humans // Paediatr. Perinat. Epidemiol. 2011. Vol. 25(1). P. 20–36. 24. Beaulieu D.B., Ananthakrishnan A.N., Issa M. et al. Budesonide induction and maintenance therapy for Crohn’s disease during pregnancy // Inflamm. Bowel Dis. 2009. Vol. 15(1). P. 25–28. 25. Van Assche G., Dignass A., Reinisch W. et al. The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: Special situations // J. Crohns Colitis. 2010. Vol. 4(1). P. 63–101. 26. Cleary B.J., Kallen B. Early pregnancy azathioprine use and pregnancy outcomes. Birth Defects Res // A Clin. Mol. Teratol. 2009. Vol. 85(7). P. 647–654. 27. Jharap B., de Boer N.K., Stokkers P. et al. Dutch Initiative on Crohn and Colitis. Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease // Gut. 2014. Vol. 63(3). P. 451–457. 28. Polifka J.E., Friedman J.M. Teratogen update: azathioprine and 6-mercaptopurine // Teratology. 2002. Vol. 65(5). P. 240–261. 29. Bar Oz. B., Hackman R., Einarson T., Koren G. Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis // Transplantation. 2001. Vol. 71(8). P. 1051–1055. 30. Bertschinger P., Himmelmann A., Risti B., Follath F. Cyclosporine treatment of severe ulcerative colitis during pregnancy // Am. J. Gastroenterol. 1995. Vol. 90(2). P. 330. 31. Baumgart D.C., Sturm A., Wiedenmann B., Dignass A.U. Uneventful pregnancy and neonatal outcome with tacrolimus in refractory ulcerative colitis // Gut. 2005. Vol. 54(12). P. 1822–1823. 32. Mahadevan U., Wolf D.C., Dubinsky M. et al. PIANO: a 1000 patient prospective registry of pregnancy outcomes in women with IBD exposed to immunomodulators and biologic therapy // Gastroenterology. 2012. Vol. 142 (Suppl. 1). P. 149. 33. Shihab Z., Yeomans N.D., De Cruz P. Anti-Tumour Necrosis Factor α Therapies and Inflammatory Bowel Disease Pregnancy Outcomes: A Meta-analysis // J Crohns Colitis. 2016. Vol. 10(8). P. 979–988. 34. De Lima A., Zelinkova Z., van der Ent C. et al. Tailored anti-TNF therapy during pregnancy in patients with IBD: maternal and fetal safety // Gut. 2016. Vol. 65 (8). P. 1261–1268. 35. Gisbert J.P., Chaparro M. Review Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease // Am. J. Gastroenterol. 2013. Vol. 108 (90). P. 1426–1438. 36. Mahadevan U., Douglas C. W., Dubinsky M. et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease // Clin. Gastroenterol. Hepatol. 2013. Vol. 11(3). P. 286–292. 37. Heller M.M., Wu J.J., Murase J.E. Fatal case of disseminated BCG infection after vaccination of an infant with in utero exposure to infliximab // J. Am. Acad. Dermatol. 2011. Vol. 65(4). P. 870. 38. Baker D.E. Adalimumab: human recombinant immunoglobulin g1 anti-tumor necrosis factor monoclonal antibody // Rev. Gastroenterol. Disord. 2004. Vol. 4(4). P. 196–210. 39. Yvette P.Y., Panaccione R., Ghosh S. et al. Management of the pregnant inflammatory bowel disease patient on antitumour necrosis factor therapy: State of the art and future directions // Can. J. Gastroenterol. Hepatol. 2014. Vol. 28(9). P. 505–509. 40. Lau A.G., Clark M., Harrison D.D. et al. Pregnancy outcomes in women exposed to golimumab // Arthritis Rheum. 2013. Vol. 65(10). P. 870–871. 41. Mariette X., Förger F., Abraham B. et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study // Ann. Rheum. Dis. 2017. Vol. 10. P. 1–6. 42. Friend S., Richman S., Bloomgren G. et al. Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study // BMC Neurology. 2016. Vol. 16(1). P. 150. 43. Haghikia A., Langer-Gould A., Rellensmann G. et al. Natalizumab use during the third trimester of pregnancy // JAMA Neurol. 2014. Vol. 71(7). P. 891–895. 44. Mahadevan U., Vermeire S., Lasch K. et al. Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease. Alimantary Pharmocology and Therapeutics // 2017. Vol. 45(7). P. 941–950.